In the interview with Healthcare de Jure (Healthcare NOW Radio), The Dedham Group’s James Pisano delves into challenges in behavioral health coverage and treatment delivery and how changes in healthcare parity legislation, benefit design, and innovative models either reshape the behavioral health environment or fall short. He also discusses how understanding these barriers helps define commercial strategy and product launch planning. Check out the full podcast episode: https://ow.ly/WmlM50R4M6f. #Healthcare #HealthcareLegislation #HealthcareIndustry #BehavioralHealth #TreatmentDelivery
The Dedham Group
Business Consulting and Services
New York, NY 16,107 followers
Management and Strategic Consulting Services
About us
The Dedham Group is the premier US oncology & specialty therapeutics strategy consulting firm that combines deep clinical expertise in specialty disease areas, commercial & market access expertise and proprietary analytics to provide highly differentiated recommendations & strategic support to our clients in the pharmaceutical and biotech industry. Our work focuses on being highly data-driven and developing highly custom and integrated strategies in exciting areas of clinical innovation which span oncology, cell & gene therapy, immunology, neurology, rare diseases and precision medicine. We are deeply embedded with our clients which span senior leaders across sales & marketing, market access, distribution & patient services, pricing & contracting and channel strategy across marquee brands on the cutting edge of clinical innovation from many of the most admired companies. Our team is comprised of highly talented entrepreneurial, collaborative and creative leaders that are focused on insights development, storytelling and creating custom strategies & products for our strategic clients, maintaining the high quality & deep specialization expectations of a boutique firm. Our organization prides itself on being a merit-driven, team-based, high-performance culture where our people care greatly about their clients’ careers, the impact of their work and the overall well-being of their colleagues.
- Website
-
http://www.dedhamgroup.com
External link for The Dedham Group
- Industry
- Business Consulting and Services
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Consulting, Healthcare, and Research
Locations
-
Primary
1 Penn Plaza
Suite 2505
New York, NY 10119, US
Employees at The Dedham Group
Updates
-
In our latest thought leadership article, Michael Hamlin covers the keys to successful portfolio optimization and how pharma companies can attain the right balance to achieve their business objectives. Read it now: https://ow.ly/4LPO50RIXqX. #PharmaOptimization #PortfolioBalance #BusinessObjectives #PharmaInsights #HealthcareStrategy #PharmaLeadership #HealthcareInnovation #ThoughtLeadership
The Portfolio Optimization Balancing Act: Keys to Improving Business Outcomes - The Dedham Group
-
Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/fM0k50RRFa6 #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies
As Sales of Weight Loss Drugs Skyrocket, the Insulin Market Falters | BioSpace
biospace.com
-
Data presented at this year’s ASCO conference reinforced the importance of patient identification. Dedham Partners Matthew Cunningham and Aaron McKeon-Fish provided an overview of the conference and the Merck + Moderna readouts for PharmaLive. Check out their insights here: https://ow.ly/oZsk50SileP
ASCO 2024 commentary: data and therapeutic standouts - PharmaLive
https://www.pharmalive.com
-
The Dedham Group stands as the premier pharmaceutical consultancy firm, renowned for its expertise in crafting, executing, and overseeing Patient Support Programs (PSPs). Partner with us for customized solutions that drive success. https://ow.ly/MoGa50REVy3
Patient Support Program Solutions - The Dedham Group
dedhamgroup.com
-
While its goal is to make drugs more affordable for patients and reduce overall drug expenditure, the FDA’s Drug Importation Program is fraught with significant challenges. The Dedham Group's Aaron McKeon-Fish shares what manufacturers need to know: https://ow.ly/WICN50Rpuz2. #HealthcareReform #DrugAffordability #PrescriptionDrugs #HealthcareCosts #PharmaIndustry
Key Considerations for Manufacturers - The Dedham Group
-
The FDA’s Drug Importation Program’s influence on pricing pressure will be modest at best for manufacturers. Here’s why: https://ow.ly/4VX250RojOM. #HealthcareReform #PrescriptionDrugs #HealthcareCosts #PharmaIndustry #DrugImportation #HealthcarePolicy
Key Considerations for Manufacturers - The Dedham Group
https://dedhamgroup.com
-
Data presented at this year’s ASCO conference reinforced the importance of patient identification. Dedham Partners Matthew Cunningham and Aaron McKeon-Fish provided an overview of the conference and the Merck + Moderna readouts for PharmaLive. Check out their insights here: https://ow.ly/uOb650SbjQ2
ASCO 2024 commentary: data and therapeutic standouts - PharmaLive
https://www.pharmalive.com
-
From digital pharmacies to other methods of virtual care, the healthcare experience is undergoing a rapid transformation, writes Tony Shi, MPH. Here’s how these new care delivery models bring new opportunities for pharma to increase value to patients: https://ow.ly/z2Pg50Rroi1. #DigitalPharmacy #VirtualCare #HealthcareInnovation #PatientCare #Telemedicine #HealthcareTransformation
How Virtual Care and Digital Pharmacies are Transforming the Healthcare Experience - The Dedham Group
https://dedhamgroup.com
-
The Dedham Group's Hannah Baxter and Jennifer (Goldenberg) Klarer, M.Sc.Eng., along with MMIT (Managed Markets Insight & Technology)'s Carolyn Zele, explain why so many patients struggle to get the genetic tests they need—and how pharma companies can help physicians find the right tests, identify the right labs, and get reimbursed. Read it here: https://ow.ly/Uaza50RG0E9. #Pharma #PharmaManufacturers #MarketAccess #Oncology
Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers | Drug Channels
drugchannels.net